PALVELLA THERAPEUTICS, INC. Cash Flow Statement
PVLA / Health Care|12 years of annual SEC 10-K data (FY2013-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 12 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$11M
FY2024
Free Cash Flow
N/A
FY2024
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2024
PALVELLA THERAPEUTICS, INC. used $11M in operating cash flow in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$17.4M | $18.7M | -$33.3M | -$37.2M | -$25.5M | -$25.5M | -$17.6M | -$22.8M | -$22.8M | -$14.1M | -$9.8M | $66.2K |
| Depreciation & Amortization | - | $1.9M | $2.8M | $2.1M | $600.0K | - | $369.0K | $361.0K | - | - | - | $384.7K |
| Operating Cash Flow | -$10.8M | -$13.7M | -$59.9M | -$45.9M | -$52.5M | -$52.5M | $49.8M | -$14.4M | -$14.4M | -$12.7M | -$15.3K | -$3.1M |
| Capital Expenditures | - | $171.0K | $1.0M | $2.7M | $2.5M | $2.5M | $1.9M | $560.0K | $560.0K | $620.7K | $267.4K | $49.5K |
| Free Cash Flow | - | -$13.9M | -$61.0M | -$48.6M | -$54.9M | -$54.9M | $47.8M | -$14.9M | -$14.9M | -$13.3M | -$282.7K | -$3.1M |
| FCF Margin | - | -32.4% | -235.4% | -165.8% | -118.7% | -118.7% | 189.1% | -256.3% | -256.3% | -454.5% | -5.3% | -25.1% |